Market
Neuralink breakthrough application achieved in human trials by end of 2025?
4
Resolution / Starting Odds
Paralysis treatment • 25%
ALS treatment • 25%
Blindness treatment • 25%
Other breakthrough • 25%
Neuralink announcements or peer-reviewed publications
Story
Neuralink to Expand Human Trials to UK, Canada, UAE, and New Zealand in 2025
Jan 9, 2025, 06:50 AM
Elon Musk's Neuralink has announced plans to expand its human trials to several countries, including the UK, Canada, New Zealand, and the UAE, in 2025. Neuralink, which develops brain-computer interface (BCI) technology, has already implanted devices in three patients. The company aims to address conditions such as paralysis, ALS, and blindness, with Musk stating that the technology could potentially enable paralyzed individuals to walk again by bypassing spinal cord damage. Human trials are currently underway in the US, UK, and Canada, with applications open for participants.
View original story
Similar markets
New treatment for epilepsy • 25%
Other significant milestone • 25%
Improved communication for paralyzed patients • 25%
Enhanced mobility for ALS patients • 25%
Other major update • 25%
New software features • 25%
Extended battery life • 25%
Increased electrode count • 25%
Case study on ALS treatment • 25%
Case study on paralysis treatment • 25%
Case study on other neurological conditions • 25%
No high-profile case study • 25%
Significant AI integration • 25%
Enables multi-device control • 25%
Achieves full sensory feedback • 25%
Other • 25%
Depression • 25%
Other condition • 25%
Epilepsy • 25%
Parkinson's disease • 25%
26 to 30 • 25%
Fewer than 20 • 25%
More than 30 • 25%
20 to 25 • 25%
Other • 25%
Improvement in speech • 25%
Restoration of leg movement • 25%
Restoration of hand movement • 25%